Compare Fresenius Kabi Onco. with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs AUROBINDO PHARMA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. AUROBINDO PHARMA FRESENIUS KABI ONCO./
AUROBINDO PHARMA
 
P/E (TTM) x 22.1 14.3 155.0% View Chart
P/BV x 3.1 3.1 100.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   AUROBINDO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
AUROBINDO PHARMA
Mar-18
FRESENIUS KABI ONCO./
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs176809 21.8%   
Low Rs79504 15.6%   
Sales per share (Unadj.) Rs37.7281.1 13.4%  
Earnings per share (Unadj.) Rs5.141.4 12.3%  
Cash flow per share (Unadj.) Rs6.750.9 13.2%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs42.5199.4 21.3%  
Shares outstanding (eoy) m158.23585.88 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.42.3 144.6%   
Avg P/E ratio x25.015.9 157.4%  
P/CF ratio (eoy) x18.912.9 146.7%  
Price / Book Value ratio x3.03.3 90.8%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m20,135384,630 5.2%   
No. of employees `0001.217.3 6.6%   
Total wages/salary Rs m70321,308 3.3%   
Avg. sales/employee Rs Th5,176.29,500.7 54.5%   
Avg. wages/employee Rs Th610.41,229.4 49.7%   
Avg. net profit/employee Rs Th699.61,397.9 50.0%   
INCOME DATA
Net Sales Rs m5,963164,666 3.6%  
Other income Rs m181,020 1.8%   
Total revenues Rs m5,981165,686 3.6%   
Gross profit Rs m1,43037,718 3.8%  
Depreciation Rs m2585,580 4.6%   
Interest Rs m-26777 -3.3%   
Profit before tax Rs m1,21632,380 3.8%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3428,183 4.2%   
Profit after tax Rs m80624,229 3.3%  
Gross profit margin %24.022.9 104.7%  
Effective tax rate %28.125.3 111.3%   
Net profit margin %13.514.7 91.9%  
BALANCE SHEET DATA
Current assets Rs m5,102121,878 4.2%   
Current liabilities Rs m2,38586,806 2.7%   
Net working cap to sales %45.621.3 213.9%  
Current ratio x2.11.4 152.3%  
Inventory Days Days150130 115.5%  
Debtors Days Days11368 165.7%  
Net fixed assets Rs m5,14881,037 6.4%   
Share capital Rs m158586 27.0%   
"Free" reserves Rs m6,556116,218 5.6%   
Net worth Rs m6,732116,804 5.8%   
Long term debt Rs m9524,512 21.1%   
Total assets Rs m10,388211,052 4.9%  
Interest coverage x-45.842.7 -107.3%   
Debt to equity ratio x0.10 366.2%  
Sales to assets ratio x0.60.8 73.6%   
Return on assets %7.511.8 63.4%  
Return on equity %12.020.7 57.7%  
Return on capital %14.627.4 53.4%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29880,727 6.6%   
Fx outflow Rs m1,77234,700 5.1%   
Net fx Rs m3,52546,027 7.7%   
CASH FLOW
From Operations Rs m1,27419,548 6.5%  
From Investments Rs m-1,204-19,570 6.2%  
From Financial Activity Rs m-1968,642 -2.3%  
Net Cashflow Rs m-1268,922 -1.4%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 9.6 27.7 34.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   42,599 69,601 61.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  AJANTA PHARMA  UNICHEM LAB  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS